

Patrick A Ott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4432559/publications.pdf>

Version: 2024-02-01

109
papers

22,019
citations

47409

49
h-index

43601

95
g-index

111
all docs

111
docs citations

111
times ranked

29906
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33. | 1.3 | 28 |
| 2 | Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. <i>Gynecologic Oncology</i> , 2022, 166, 211-218. | 0.6 | 20 |
| 3 | Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538. | 13.7 | 70 |
| 4 | PD-1 Inhibitionâ€™Trouble for Subsequent TIL Therapy in Patients with Melanoma?. <i>Clinical Cancer Research</i> , 2022, 28, 2980-2982. | 3.2 | 2 |
| 5 | Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. <i>JCO Precision Oncology</i> , 2022, , . | 1.5 | 11 |
| 6 | Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 215-229. | 12.5 | 486 |
| 7 | Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2209-2221. | 2.0 | 32 |
| 8 | Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100133. | 2.5 | 32 |
| 9 | Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , 2021, 27, 515-525. | 15.2 | 248 |
| 10 | Personal Neoantigen Vaccines for the Treatment of Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 259-276. | 2.3 | 13 |
| 11 | Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021, 10, 2627-2635. | 1.3 | 5 |
| 12 | Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121. | | 30 |
| 13 | Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 35-44. | 0.6 | 4 |
| 14 | Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. , 2021, 9, e002932. | | 7 |
| 15 | CX-072 (pacmilimab), a Probody^{â€™} PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447. | | 26 |
| 16 | CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. , 2021, 9, e002446. | | 16 |
| 17 | Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125. | 13.7 | 239 |
| 18 | A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205. | 2.6 | 95 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Long-term Overall Survival and Predictors in Anti-PD-1-naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021, 44, 307-318. | 1.2 | 4 |
| 20 | Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect. <i>Cancer Cell</i> , 2021, 39, 1458-1460. | 7.7 | 0 |
| 21 | Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318. | | 7 |
| 22 | A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020, 183, 347-362.e24. | 13.5 | 349 |
| 23 | Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. , 2020, 8, e000992. | | 4 |
| 24 | Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. <i>Cell Reports Medicine</i> , 2020, 1, 100141. | 3.3 | 25 |
| 25 | Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. <i>JCO Oncology Practice</i> , 2020, 16, e933-e942. | 1.4 | 33 |
| 26 | Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. <i>Cancer</i> , 2020, 126, 3758-3767. | 2.0 | 37 |
| 27 | Directing Traffic: How to Effectively Drive T Cells into Tumors. <i>Cancer Discovery</i> , 2020, 10, 185-197. | 7.7 | 68 |
| 28 | Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. <i>Scientific Reports</i> , 2020, 10, 723. | 1.6 | 21 |
| 29 | The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. <i>Oncologist</i> , 2020, 25, 505-514. | 1.9 | 93 |
| 30 | Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289. | | 19 |
| 31 | A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. <i>Cancer</i> , 2019, 125, 1113-1123. | 2.0 | 45 |
| 32 | Intralesional Cancer Immunotherapies. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 249-260. | 0.9 | 10 |
| 33 | Immunotherapy: An Old and New Modality for the Treatment of Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, xi-xii. | 0.9 | 0 |
| 34 | An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e70-e78. | 1.8 | 35 |
| 35 | Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 199. | 1.3 | 9 |
| 36 | Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. <i>Cancer Discovery</i> , 2019, 9, 476-481. | 7.7 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. , 2019, 7, 89. | | 108 |
| 38 | T-Cellâ€œInflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology, 2019, 37, 318-327. | 0.8 | 656 |
| 39 | Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565, 234-239. | 13.7 | 956 |
| 40 | The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. International Journal of Radiation Oncology Biology Physics, 2019, 103, 142-151. | 0.4 | 118 |
| 41 | Pembrolizumab in patients with programmed death ligand 1â€œpositive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecologic Oncology, 2019, 152, 243-250. | 0.6 | 192 |
| 42 | Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer, 2018, 124, 1111-1121. | 2.0 | 72 |
| 43 | Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. , 2018, 6, 26. | | 150 |
| 44 | Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptorâ€œPositive/Human Epidermal Growth Factor Receptor 2â€œNegative Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 2804-2811. | 3.2 | 249 |
| 45 | Immune-modified response criteria â€œ an iterative learning process?. Nature Reviews Clinical Oncology, 2018, 15, 267-268. | 12.5 | 5 |
| 46 | <i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215. | 7.7 | 392 |
| 47 | Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 2018, 18, 168-182. | 10.6 | 736 |
| 48 | Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Research, 2018, 28, 605-610. | 0.6 | 24 |
| 49 | Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Current Oncology Reports, 2018, 20, 1. | 1.8 | 30 |
| 50 | A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013. Journal of the American Academy of Dermatology, 2018, 79, 921-928. | 0.6 | 2 |
| 51 | Pan-tumor genomic biomarkers for PD-1 checkpoint blockadeâ€œbased immunotherapy. Science, 2018, 362, . | 6.0 | 1,575 |
| 52 | A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018, 175, 984-997.e24. | 13.5 | 892 |
| 53 | Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunology, Immunotherapy, 2018, 67, 1833-1844. | 2.0 | 52 |
| 54 | A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood, 2018, 132, 1911-1921. | 0.6 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204. | 6.6 | 400 |
| 56 | Combination immunotherapy: a road map. , 2017, 5, 16. | | 325 |
| 57 | Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 312-318. | 1.6 | 354 |
| 58 | Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 43-50. | 2.7 | 23 |
| 59 | Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 344-351. | 0.4 | 143 |
| 60 | Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. <i>Cancer Immunology Research</i> , 2017, 5, 286-291. | 1.6 | 49 |
| 61 | Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362. | 1.6 | 40 |
| 62 | Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. <i>Clinical Cancer Research</i> , 2017, 23, 4671-4679. | 3.2 | 110 |
| 63 | Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140. | 1.6 | 114 |
| 64 | An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221. | 18.7 | 2,112 |
| 65 | Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103. | 0.3 | 51 |
| 66 | Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222. | 3.2 | 44 |
| 67 | Regression of multifocal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. , 2017, 5, 61. | | 5 |
| 68 | Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66. | | 37 |
| 69 | PD-1 inhibitors in endometrial cancer. <i>Oncotarget</i> , 2017, 8, 106169-106170. | 0.8 | 15 |
| 70 | Reply to F. Tomao et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 3633-3634. | 0.8 | 0 |
| 71 | Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3823-3829. | 0.8 | 413 |
| 72 | Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 4035-4041. | 0.8 | 375 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€“Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2535-2541. | 0.8 | 383 |
| 74 | Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. <i>Journal of Neuro-Oncology</i> , 2016, 129, 389-393. | 1.4 | 7 |
| 75 | Talimogene Laherparepvec for the Treatment of Advanced Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3127-3131. | 3.2 | 80 |
| 76 | Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26. | | 10 |
| 77 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598. | 5.1 | 594 |
| 78 | Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3562-3569. | 0.8 | 175 |
| 79 | Clinical outcomes in metastatic uveal melanoma treated with PDâ€“1 and PDâ€“L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353. | 2.0 | 288 |
| 80 | The efficacy of antiâ€“PDâ€“1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362. | 2.0 | 236 |
| 81 | PD-1 Inhibitorâ€“Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060. | 3.2 | 393 |
| 82 | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1558-1568. | 5.1 | 827 |
| 83 | Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647. | 2.6 | 524 |
| 84 | Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234. | 3.4 | 534 |
| 85 | Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. <i>Frontiers in Oncology</i> , 2015, 5, 202. | 1.3 | 201 |
| 86 | Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. <i>Clinical Cancer Research</i> , 2015, 21, 749-755. | 3.2 | 223 |
| 87 | Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 986-991. | 1.6 | 21 |
| 88 | Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 278-287. | 1.6 | 81 |
| 89 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017. | 13.9 | 2,489 |
| 90 | Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59. | 1.8 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1185-1192. | 1.6 | 227 |
| 92 | A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. <i>Oncolmmunology</i> , 2015, 4, e1046028. | 2.1 | 191 |
| 93 | Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, 313. | 0.7 | 3 |
| 94 | New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. <i>Drug, Healthcare and Patient Safety</i> , 2014, 6, 77. | 1.0 | 32 |
| 95 | The Biology and Clinical Development of MEK Inhibitors for Cancer. <i>Drugs</i> , 2014, 74, 2111-2128. | 4.9 | 35 |
| 96 | Phase I/II Study of the Antibody-Drug Conjugate Glematumumab Vedotin in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3659-3666. | 0.8 | 72 |
| 97 | Vaccines and Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 559-569. | 0.9 | 20 |
| 98 | HLA-Binding Properties of Tumor Neopeptides in Humans. <i>Cancer Immunology Research</i> , 2014, 2, 522-529. | 1.6 | 194 |
| 99 | Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. <i>Investigational New Drugs</i> , 2013, 31, 425-434. | 1.2 | 123 |
| 100 | Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 811-822. | 2.0 | 97 |
| 101 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 183-191. | 1.1 | 40 |
| 102 | CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. <i>Clinical Cancer Research</i> , 2013, 19, 5300-5309. | 3.2 | 596 |
| 103 | Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function. <i>Frontiers in Immunology</i> , 2013, 4, 346. | 2.2 | 36 |
| 104 | The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. <i>Chinese Clinical Oncology</i> , 2013, 2, 7. | 0.4 | 9 |
| 105 | Surgical Approach to Primary Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 39-56. | 0.6 | 12 |
| 106 | Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. <i>Immunotherapy</i> , 2011, 3, 213-227. | 1.0 | 53 |
| 107 | A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates. <i>PLoS ONE</i> , 2010, 5, e15588. | 1.1 | 90 |
| 108 | A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma. <i>PLoS ONE</i> , 2010, 5, e8714. | 1.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma. <i>Chemotherapy</i> , 2009, 55, 221-227. | 0.8 | 24 |